Original Research
Published on 09 Jan 2024
Cost-effectiveness of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with highvolume, metastatic, hormone-sensitive prostate cancer
in Drugs Outcomes Research and Policies

- 287 views











